drugset / Trial / NCT00629824

Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C

NCT00629824

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection. The efficacy and safety of pegylated interferon-alpha plus ribavirin combination therapy and its impact on the outcome in older patients with chronic hepatitis C deserve to be elucidated. The purposes of this study are: 1. To evaluate the efficacy of pegylated interferon-alpha 2a plus ribavirin combination therapy in older patients with chronic hepatitis C 2. To investigate the safety of pegylated interferon-alpha 2a plus ribavirin combination therapy in older patients with chronic hepatitis C

Timeline

Start
2007-02
Primary completion
2009-04
Completion
2009-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Peginterferon alfa-2a Protein / enzyme biologic 180 ug
Comparator Ribavirin Small molecule 1000 mg
Comparator Ribavirin Small molecule 1200 mg